首页> 外文期刊>Pharmaceutical research >Novel biotinylated lipid prodrugs of acyclovir for the treatment of herpetic keratitis (HK): Transporter recognition, tissue stability and antiviral activity
【24h】

Novel biotinylated lipid prodrugs of acyclovir for the treatment of herpetic keratitis (HK): Transporter recognition, tissue stability and antiviral activity

机译:阿昔洛韦用于治疗疱疹性角膜炎(HK)的新型生物素化脂质前药:转运蛋白识别,组织稳定性和抗病毒活性

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Biotinylated lipid prodrugs of acyclovir (ACV) were designed to target the sodium dependent multivitamin transporter (SMVT) on the cornea to facilitate enhanced cellular absorption of ACV. Methods: All the prodrugs were screened for in vitro cellular uptake, interaction with SMVT, docking analysis, cytotoxicity, enzymatic stability and antiviral activity. Results: Uptake of biotinylated lipid prodrugs of ACV (B-R-ACV and B-12HS-ACV) was significantly higher than biotinylated prodrug (B-ACV), lipid prodrugs (R-ACV and 12HS-ACV) and ACV in corneal cells. Transepithelial transport across rabbit corneas indicated the recognition of the prodrugs by SMVT. Average Vina scores obtained from docking studies further confirmed that biotinylated lipid prodrugs possess enhanced affinity towards SMVT. All the prodrugs studied did not cause any cytotoxicity and were found to be safe and non-toxic. B-R-ACV and B-12HS-ACV were found to be relatively more stable in ocular tissue homogenates and exhibited excellent antiviral activity. Conclusions: Biotinylated lipid prodrugs demonstrated synergistic improvement in cellular uptake due to recognition of the prodrugs by SMVT on the cornea and lipid mediated transcellular diffusion. These biotinylated lipid prodrugs appear to be promising drug candidates for the treatment of herpetic keratitis (HK) and may lower ACV resistance in patients with poor clinical response.
机译:目的:阿昔洛韦(ACV)的生物素化脂质前药被设计为靶向角膜上的钠依赖性多种维生素转运蛋白(SMVT),以促进ACV的细胞吸收增强。方法:筛选所有前药的体外细胞吸收,与SMVT的相互作用,对接分析,细胞毒性,酶稳定性和抗病毒活性。结果:ACV(B-R-ACV和B-12HS-ACV)的生物素化脂质前体药物的摄取显着高于角膜细胞中生物素化的前体药物(B-ACV),脂质前体药物(R-ACV和12HS-ACV)和ACV。跨兔角膜的上皮运输表明SMVT对前药的识别。从对接研究获得的平均Vina分数进一步证实,生物素化的脂质前药对SMVT的亲和力增强。研究的所有前药均未引起任何细胞毒性,并且被发现是安全且无毒的。发现B-R-ACV和B-12HS-ACV在眼组织匀浆中相对更稳定,并表现出出色的抗病毒活性。结论:由于在角膜上通过SMVT识别前药和脂质介导的跨细胞扩散,生物素化的脂质前药显示出细胞摄取的协同改善。这些生物素化的脂质前药似乎是治疗疱疹性角膜炎(HK)的有前途的候选药物,并且可能降低临床反应较差的患者的ACV抵抗力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号